Total Payments
$225,251
2023 Payments
$15,125
Companies
10
Transactions
136
Payment Breakdown by Category
Consulting$106,729 (47.4%)
Research$66,050 (29.3%)
Other$50,012 (22.2%)
Travel$2,083 (0.9%)
Food & Beverage$361.03 (0.2%)
Education$16.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $106,729 | 45 | 47.4% |
| Unspecified | $66,050 | 74 | 29.3% |
| Honoraria | $50,012 | 6 | 22.2% |
| Travel and Lodging | $2,083 | 5 | 0.9% |
| Food and Beverage | $361.03 | 5 | 0.2% |
| Education | $16.09 | 1 | 0.0% |
Payments by Type
General
$159,201
62 transactions
Research
$66,050
74 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $91,853 | 33 | $0 (2019) |
| Jubilant Therapeutics Inc | $50,898 | 9 | $0 (2023) |
| AbbVie Inc. | $46,925 | 43 | $0 (2020) |
| TESARO, Inc. | $18,125 | 26 | $0 (2019) |
| PFIZER INC. | $6,940 | 11 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $4,500 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $3,568 | 2 | $0 (2019) |
| Genentech, Inc. | $1,254 | 2 | $0 (2018) |
| GlaxoSmithKline, LLC. | $1,000 | 5 | $0 (2023) |
| Amgen Inc. | $188.58 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $15,125 | 2 | Jubilant Therapeutics Inc ($15,000) |
| 2022 | $8,386 | 4 | Jubilant Therapeutics Inc ($8,386) |
| 2021 | $16,600 | 3 | Jubilant Therapeutics Inc ($15,000) |
| 2020 | $14,137 | 11 | Jubilant Therapeutics Inc ($12,512) |
| 2019 | $46,493 | 31 | AbbVie, Inc. ($34,525) |
| 2018 | $44,087 | 37 | Merck Sharp & Dohme Corporation ($25,270) |
| 2017 | $80,423 | 48 | Merck Sharp & Dohme Corporation ($64,183) |
All Payment Transactions
136 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/30/2023 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $15,000.00 | General |
| 03/23/2023 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | ||||||
| 11/07/2022 | Jubilant Therapeutics Inc | — | Travel and Lodging | Cash or cash equivalent | $402.68 | General |
| 08/17/2022 | Jubilant Therapeutics Inc | — | Travel and Lodging | Cash or cash equivalent | $392.51 | General |
| 08/17/2022 | Jubilant Therapeutics Inc | — | Food and Beverage | Cash or cash equivalent | $90.41 | General |
| 07/15/2022 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $7,500.00 | General |
| 12/20/2021 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $7,500.00 | General |
| 11/03/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 05/21/2021 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $7,500.00 | General |
| 11/25/2020 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $7,500.00 | General |
| 08/10/2020 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $250.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | ||||||
| 07/13/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: M12-914 | ||||||
| 06/08/2020 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $375.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | ||||||
| 04/13/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: M12-914 | ||||||
| 04/13/2020 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | ||||||
| 03/09/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: M12-914 | ||||||
| 02/19/2020 | Jubilant Therapeutics Inc | — | Honoraria | Cash or cash equivalent | $5,012.00 | General |
| 02/10/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: M12-914 | ||||||
| 01/21/2020 | AbbVie Inc. | — | — | Cash or cash equivalent | $250.00 | Research |
| Study: M12-914 | ||||||
| 01/16/2020 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | ||||||
| 12/12/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $375.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 11/27/2019 | AbbVie, Inc. | — | — | Cash or cash equivalent | $125.00 | Research |
| Study: M12-914 | ||||||
| 11/27/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 11/06/2019 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | Cash or cash equivalent | $3,534.00 | General |
| 11/06/2019 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $33.96 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M12-914 | AbbVie, Inc. | $44,875 | 32 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $18,125 | 26 |
| M12-895 | AbbVie, Inc. | $1,300 | 6 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | GlaxoSmithKline, LLC. | $1,000 | 5 |
| M12-914 | AbbVie Inc. | $750.00 | 5 |
About William Hahn, MD PHD
William Hahn, MD PHD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457313652.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, William Hahn, MD PHD has received a total of $225,251 in payments from pharmaceutical and medical device companies, with $15,125 received in 2023. These payments were reported across 136 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($106,729).
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 04/04/2006
- Last Updated 11/13/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1457313652
Products in Payments
- KEYTRUDA (Biological) $91,755
- ZEJULA (Drug) $18,125
- SUTENT (Drug) $5,340
- NO PRODUCT DISCUSSED (Drug) $3,568
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701